From - Diagnostic Testing & Emerging Technologies
The FY 2018 omnibus appropriations bill, passed by Congress in late March, included a little noticed provision that could ultimately bring significant changes to the laboratory industry…
From - Diagnostic Testing & Emerging Technologies
There is not enough evidence, currently, to support the routine adoption of liquid biopsy tests for any of its promising clinical uses, according to a joint review published…
